How PD-L1 Biomarker Test Results Impact Clinical Management of Lung CancerVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Dr. Steve O’Day discusses the current state of cancer treatments, which focuses less on standard chemotherapy and has begun relying more on targeted therapies and immune-oncology.
Dr. Gary Palmer discusses the different profile of tumors and how to make findings as general as possible to better treat the patient.